FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000640630> ?p ?o ?g. }

• W2000640630 endingPage "e84409" @default.
• W2000640630 startingPage "e84409" @default.
• W2000640630 abstract "Increasing resistance to every major class of antibiotics and a dearth of novel classes of antibacterial agents in development pipelines has created a dwindling reservoir of treatment options for serious bacterial infections. The bacterial type IIA topoisomerases, DNA gyrase and topoisomerase IV, are validated antibacterial drug targets with multiple prospective drug binding sites, including the catalytic site targeted by the fluoroquinolone antibiotics. However, growing resistance to fluoroquinolones, frequently mediated by mutations in the drug-binding site, is increasingly limiting the utility of this antibiotic class, prompting the search for other inhibitor classes that target different sites on the topoisomerase complexes. The highly conserved ATP-binding subunits of DNA gyrase (GyrB) and topoisomerase IV (ParE) have long been recognized as excellent candidates for the development of dual-targeting antibacterial agents with broad-spectrum potential. However, to date, no natural product or small molecule inhibitors targeting these sites have succeeded in the clinic, and no inhibitors of these enzymes have yet been reported with broad-spectrum antibacterial activity encompassing the majority of Gram-negative pathogens. Using structure-based drug design (SBDD), we have created a novel dual-targeting pyrimidoindole inhibitor series with exquisite potency against GyrB and ParE enzymes from a broad range of clinically important pathogens. Inhibitors from this series demonstrate potent, broad-spectrum antibacterial activity against Gram-positive and Gram-negative pathogens of clinical importance, including fluoroquinolone resistant and multidrug resistant strains. Lead compounds have been discovered with clinical potential; they are well tolerated in animals, and efficacious in Gram-negative infection models." @default.
• W2000640630 created "2016-06-24" @default.
• W2000640630 creator A5013256247 @default.
• W2000640630 creator A5013577208 @default.
• W2000640630 creator A5020056606 @default.
• W2000640630 creator A5021398621 @default.
• W2000640630 creator A5024762909 @default.
• W2000640630 creator A5025031597 @default.
• W2000640630 creator A5026266602 @default.
• W2000640630 creator A5027409273 @default.
• W2000640630 creator A5032353853 @default.
• W2000640630 creator A5038492903 @default.
• W2000640630 creator A5039881624 @default.
• W2000640630 creator A5043711375 @default.
• W2000640630 creator A5045483874 @default.
• W2000640630 creator A5049077059 @default.
• W2000640630 creator A5054819415 @default.
• W2000640630 creator A5055041718 @default.
• W2000640630 creator A5058399753 @default.
• W2000640630 creator A5058481329 @default.
• W2000640630 creator A5071052307 @default.
• W2000640630 creator A5077275234 @default.
• W2000640630 creator A5078641399 @default.
• W2000640630 creator A5078707644 @default.
• W2000640630 creator A5079820709 @default.
• W2000640630 creator A5084334848 @default.
• W2000640630 creator A5084461414 @default.
• W2000640630 creator A5086601088 @default.
• W2000640630 creator A5090249918 @default.
• W2000640630 date "2013-12-26" @default.
• W2000640630 modified "2023-09-29" @default.
• W2000640630 title "Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents" @default.
• W2000640630 cites W1970798262 @default.
• W2000640630 cites W1974672939 @default.
• W2000640630 cites W1978681980 @default.
• W2000640630 cites W1979474715 @default.
• W2000640630 cites W1980082881 @default.
• W2000640630 cites W1980482232 @default.
• W2000640630 cites W1985588649 @default.
• W2000640630 cites W1986191025 @default.
• W2000640630 cites W2010463671 @default.
• W2000640630 cites W2014989916 @default.
• W2000640630 cites W2037001581 @default.
• W2000640630 cites W2047245810 @default.
• W2000640630 cites W2049245087 @default.
• W2000640630 cites W2069270290 @default.
• W2000640630 cites W2071325808 @default.
• W2000640630 cites W2074986801 @default.
• W2000640630 cites W2077451485 @default.
• W2000640630 cites W2093742668 @default.
• W2000640630 cites W2099617977 @default.
• W2000640630 cites W2105668062 @default.
• W2000640630 cites W2119567467 @default.
• W2000640630 cites W2122273366 @default.
• W2000640630 cites W2124525553 @default.
• W2000640630 cites W2125634299 @default.
• W2000640630 cites W2132175878 @default.
• W2000640630 cites W2138848871 @default.
• W2000640630 cites W2139516496 @default.
• W2000640630 cites W2163341755 @default.
• W2000640630 cites W2166761684 @default.
• W2000640630 cites W2166765429 @default.
• W2000640630 cites W2793938485 @default.
• W2000640630 doi "https://doi.org/10.1371/journal.pone.0084409" @default.
• W2000640630 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3873466" @default.
• W2000640630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24386374" @default.
• W2000640630 hasPublicationYear "2013" @default.
• W2000640630 type Work @default.
• W2000640630 sameAs 2000640630 @default.
• W2000640630 citedByCount "83" @default.
• W2000640630 countsByYear W20006406302014 @default.
• W2000640630 countsByYear W20006406302015 @default.
• W2000640630 countsByYear W20006406302016 @default.
• W2000640630 countsByYear W20006406302017 @default.
• W2000640630 countsByYear W20006406302018 @default.
• W2000640630 countsByYear W20006406302019 @default.
• W2000640630 countsByYear W20006406302020 @default.
• W2000640630 countsByYear W20006406302021 @default.
• W2000640630 countsByYear W20006406302022 @default.
• W2000640630 countsByYear W20006406302023 @default.
• W2000640630 crossrefType "journal-article" @default.
• W2000640630 hasAuthorship W2000640630A5013256247 @default.
• W2000640630 hasAuthorship W2000640630A5013577208 @default.
• W2000640630 hasAuthorship W2000640630A5020056606 @default.
• W2000640630 hasAuthorship W2000640630A5021398621 @default.
• W2000640630 hasAuthorship W2000640630A5024762909 @default.
• W2000640630 hasAuthorship W2000640630A5025031597 @default.
• W2000640630 hasAuthorship W2000640630A5026266602 @default.
• W2000640630 hasAuthorship W2000640630A5027409273 @default.
• W2000640630 hasAuthorship W2000640630A5032353853 @default.
• W2000640630 hasAuthorship W2000640630A5038492903 @default.
• W2000640630 hasAuthorship W2000640630A5039881624 @default.
• W2000640630 hasAuthorship W2000640630A5043711375 @default.
• W2000640630 hasAuthorship W2000640630A5045483874 @default.
• W2000640630 hasAuthorship W2000640630A5049077059 @default.
• W2000640630 hasAuthorship W2000640630A5054819415 @default.
• W2000640630 hasAuthorship W2000640630A5055041718 @default.
• W2000640630 hasAuthorship W2000640630A5058399753 @default.

• next